Nanoparticle-based delivery systems have become a popular method for targeting tumors and impermeable tissue with drugs for treatment and imaging markers for biodetection. Nanomaterials are beneficial for medical treatment because they can be modified to have increased stability and carrying capacity, and their size and surface modifications allow them to reach otherwise impenetrable tissue. Localized or systemic injection can be used for delivery of nanoparticles; however, systemic injection without appropriate surface modifications is subjected to uptake by the mononuclear phagocytic system which clears particles from the circulation rapidly limiting their accumulation at target tissue and reducing efficacy. Here we demonstrate the biodistribution of Yttrium oxyorthosilicate nanoparticles doped with Cerium after localized injection to the cerebral cortex as well as the immune response at the site of injection over time. 
Introduction
Nanoparticles have become an increasingly popular tool for many applications ranging from diagnostics to drug delivery and targeted therapies (Soppimath 2001 , Faraji 2009 , Bahrami 2017 . Much research has gone into the development of nanomaterials that are biocompatible and do not elicit a deleterious immune response. Despite this enormous promise of this emerging technology, issues with the delivery, targeting, toxicity and clearance of nanoparticle-based drug delivery systems leave many unresolved questions (Longmire 2008 , Ray 2009 ). One strategy currently in development is to modify the surface chemistries of nanoparticles in such a way as to address these concerns, aiming to alter particles in ways that promote stability and minimize toxicity (Kango 2013 ).
In addition to modifying surface chemistries, researchers have also taken advantage of the fact that nanoparticles generated from different starting materials also display an enormous amount of variability in their biocompatibility and utility (Faraji 2009 ).
Silicon-based nanoparticles have been especially extensively probed for potential medical applications due to their low inherent toxicity, especially when administered chronically (Murugadoss 2017) . Wide band gap materials doped with rare earth ions are under intense research for their applications in medical imaging and have been used in the development of PET detectors for their scintillating properties (Loudyi 2007 ). More recently however, rare earth orthosilicates such as yttrium orthosilicate doped with cerium Y2SiO5:Ce (YSO:Ce) have been studied for their additional scintillating properties (Ricci 2008 , Hamroun 2018 . Scintillating nanoparticles provide a popular platform for biomedical applications because of their ability to produce light upon stimulation that can be detected through multiple imaging modalities. Scintillating materials such as YSO:Ce allow investigators to deliver specific spectra of light to targeted areas that can be utilized in applications such as optogenetic manipulations (Melcher 2000 , Pignalosa 2012 ).
YSO:Ce's specific blue light emission spectrum, typically used in LEDs and phosphors, may provide a novel light delivery method to the brain inhibited by minimal light scatter (Krämer 2003 , Gonzales-Ortega 2005 .
Currently, in vivo optogenetic methods require the use of an implantable optical fiber into a target tissue expressing a genetically encoded bacterial opsin consisting of a channel protein capable of excitation upon stimulation with specific wavelengths (Cardin 2010 ). Scintillating nanoparticles could potentially be designed which emit a tunable spectra of visible light to replace currently used optical fiber-based approaches. Cell type specific expression of optically-activated constructs paired with light stimulation from localized scintillating nanoparticles provides a far less invasive platform for optogenetic experiments than current available methods of intracranial light delivery, such as surgical implantation of optical fibers. Previous work has demonstrated that only a median of 0.7% of systemically injected nanoparticles passively reached their target tissue, which limits the efficacy of these particles to barely appreciable levels (Wilhelm 2016) . In addition to issues of ineffective passive distribution, the mononuclear phagocytic system also represents a significant barrier to the focal delivery of particles to target tissues (Wei 2018 ). Intracranial injection of nanoparticles to a target region would bypass the phagocytic system and allow for specific localization of particles to a brain regions of interest. Additionally, nanoparticles can be designed with surface modifications that tether them in close proximity to their sensors to provide more directed light stimulation in a cellspecific manner and increase their chemical stability.
Despite these promises, little is currently known regarding the biodistribution or toxicity of scintillating particles delivered via intracranial injection. In the current study, we examined the biodistribution of, and inflammatory response mounted against scintillating nanoparticles delivered into mouse cerebral cortex in order to determine the feasibility and efficacy of utilizing these particles for in vivo stimulation in future studies. C57BL/6J mice were given intracranial delivery of YSO-BSA-fluorescein (FITC) nanoparticles at differing concentrations targeting premotor cortex (M2) as it is a commonly targeted area in optogenetic experiments. Follow infusion, we examined the distribution and neuro inflammatory response was measured each at specific post-infusion time points.
Methods:

Synthesis of Yttrium orthosilicate nanoparticles
Sub 100 nm silica cores were synthesized by the sol-gel process with 27 mmol (6.0 mL) of tetra ethyorthosilicate, 167 mmol (3 mL) of water, and 50 mmol (2 mL) of ammonia hydroxide (28% v/v) in 150 mL of ethanol at room temperature under vigorous stirring condition for 20 hrs. The particles were then washed with ethanol (2x) and water (1x).
Silica (120 mg) was disperse in water (100 mL) with 1.98 mmol (760 mg) of yttrium nitrate hexahydrate and 15 µmol (6.5 mg) of cerium nitrate hexahydrate. Ammonia hydroxide (1 mL) was added drop wise into the solution and vigorously stirred for 16 hrs in room temperature. The waters were washed with water (3x) and dried at 125OC. The particles were annealed at 1000 o C for 1 hr.
Characterization of core-shell yttrium orthosilicate nanoparticles
Sub 100 nm particulates were dispersed in water on double-sided carbon tape and mounted onto a scanning electron microscope stub. The particles were plasma coated with platinum. A Hitachi 4800 scanning electron microscope was used to image the particles at 20 kV and 10 mA. Photoluminescence and excitation measurements were taken by a Jobin Yvon Fluorolog 3-222 spectrometer with a pump source of 360 nm. Xray luminescence was measured with a Horiba JY synapse CCD camera, Horiba JY microHR monochromator, and a tungsten target Amptek mini x-ray source at 40 kV and 99 µA.
Experimental subjects
Female C57BL/6J mice (The Jackson Laboratory, Bar Harbor, ME) were housed in a temperature-and humidity-controlled vivarium under a reverse 12 h light/dark cycle (lights off 0800 h). All experimental procedures were performed in accordance with the National Institutes of Health Guide for Care and Use of Laboratory Animals and were approved by the University of New Mexico Health Sciences Center Institutional Animal Care and Use Committee.
Microinjection of Nanoparticles
At approximately 6 months of age, mice were anesthetized with isoflurane and fixed in a 1:500; Neuromab, USA) and polyclonal rabbit anti-IBA-1 (dilution: 1:250; Wako, Japan) diluted in 5% donkey serum and 0.25% Triton X-100 brought to volume in PBS. Sections were covered and incubated in a 4˚C walk-in cold room overnight. The following day, the primary antibody solution was removed and slices were washed 3 times with 500µL PBS for 5 minutes each. Following the three washes, 500µL of secondary antibody solution containing donkey anti-mouse AlexaFluor 647 (dilution: 1:500; Abcam, USA) and donkey anti-rabbit AlexaFluor 550 (dilution: 1:500; Abcam, USA) diluted in 5% donkey serum and 0.25% Triton X-100 brought to volume in PBS was added to the sections at room temperature for 1 hour. After this incubation the secondary antibody solution was removed and slices were washed 3 times with 500 µL 1xPBS for 5 minutes each. DAPI counterstaining (1:5000 concentration in PBS) was then performed and slices were placed on a rocker for 10 minutes shielded from light. Finally, the slices were washed 3 times with 500µL PBS for 5 minutes each and mounted to glass microscope slides. Slices were covered with 100µL of Fluoromount-G (Thermo Fischer Scientific, USA) and then sealed with glass coverslips, making sure to remove any air bubbles. Slides were finally stored in a 4˚C refrigerator for subsequent imaging.
Confocal Microscopy
Following immunostaining and mounting, nanoparticle-tagged FITC and fluorescencetagged immune cell populations were imaged using a Leica TCS SP8 Confocal Microscope (Leica Microsystems). DAPI, nanoparticle-conjugated FITC and secondary antibody-conjugated fluorophores were excited using a 405nm laser diode and a tunable pulse white light laser, respectively, with a 10x air objective and a 63x oil immersion objective and captured using hybrid spectral detectors (HyD). Z-stacks were then collected with a Z-range of 70µm. Z stacks of adjacent slices were ordered and merged to estimate the extent of the nanoparticle spread and compressed then into a two dimensional image using the maximal intensity projection algorithm in the Leica LASX software package. Maximum projection maps were exported as uncompressed TIFF files and transferred to ImageJ image analysis software.
Analysis and Statistics
Optical sections of 25µm thickness were collected for the brains that were sectioned and stained for quantification of NP-FITC, IBA-1 and GFAP signals, respectively. After Z stacks were compressed, ImageJ software was used to draw regions of interest (ROIs) surrounding the entire extent of the M2 region with the help of the Allen Brain Atlas for the given appropriate A/P range. Light signal from photon scatter around the edges of tissue, tears in the tissue as wells as vasculature were excluded from analysis. Mean fluorescence intensities were calculated over the ROIs, and a background measurement taken from cortical regions outside M2 was subtracted from these values to normalize for the autofluorescent and nonspecific signal present in the sample. A ratio was then calculated for signal intensity in the NP vs. vehicle treated hemispheres and mean values with SEM were reported for each time point. ImageJ was scaled such that the pixel to mm ratio was defined for each image and using this scale, the area of the extent of NP spread was calculated by manually tracing the outlines of the FITC signal adjacent to the site of injection. Two-tailed, unpaired t-tests were conducted to compare replicate MFI values across time points.
Results:
To determine the extent of spread of injected nanoparticles, animals that received the particles were sacrificed 24 hours, 48 hours and 9 days post injection and the FITC fluorophore conjugated to the nanoparticles was imaged across the extent of the M2 region. Confocal imaging of the region surrounding the injection site revealed reliably detectable FITC in non-perfused animals ( Figure 3A, D) , but no detectable signal in animals that were perfused with 4% PFA upon sacrifice (data not shown). In the nonperfused groups, 50µm slices were immunostained for the astrocytic marker glial fibrillary acidic protein (GFAP) as well as the microglial marker allograft inflammatory marker 1 (IBA-1) for subsequent analyses ( Figure 3B , E). Due to light scatter in the sample along edges and tears in the tissue, as well as from vasculature giving off fluorescent signal in addition to our sample, care was taken to exclude these confounds from analysis ( Figure   3C , D). With this in mind, we set out to quantify the area and intensity of the spread of NPs as well as the presence of inflammatory cells in the M2 region.
To accomplish this quantification, Z stacks were collected across the extent of the M2-containing brain sections and 3D interpretations were reconstructed with Leica LASX software ( Figure 4A ). Based on this 3D reconstruction it was determined that the injected NPs spread to fill an area of approximately 0.091mm3 in the 24hr group, 0.097mm3 in the 48hr group and just 0.0101mm3 in the long term group ( Figure 4B ). The drop in signal intensity adjacent to the injection site between the 72 hour and 9 day time points could potentially indicate either an active clearance of the particles to the lymphatic system, or a passive diffusion of the particles through the M2 region away from the injury site between those two time points. To address this difference in mechanisms, Z stacks were then flattened according to a maximal intensity projection algorithm and ImageJ software was utilized to measure mean fluorescence intensity (MFI) for the NP-FITC signaling across the entire extent of the M2 region from both the NP injected (ipsilateral) and vehicle-injected (contralateral) sides. These fluorescence measurements were normalized to a cortical background fluorescence level outside the M2 region to control for nonspecific signal, and are shown as a ratio of the intensity of the FITC signal in hemisphere ipsilateral to the injection over the contralateral side ( Figure 4C ).
Interestingly, while the size of the relatively bright NP-FITC signal adjacent to the injection site diminished notably by the 9 day time point, no difference was established in the overall mean fluorescence intensity across M2 in the same time frame, indicating the likely persistence of NPs in the M2 region, likely due to passive diffusion from the site rather than clearance from the tissue overall.
As previously noted, brain sections were additionally stained with antibodies against astrocyte marker GFAP as well as microglial marker IBA-1 near the injection site to determine whether or not the brain immune system mounted an inflammatory response to the presence of the particles. Representative images for each the IBA-1 ( Figure 5A) and the GFAP ( Figure 5B ) staining, respectively, show that both glial cell types were readily detectable in the mouse gray matter following NP injection. Maximal projection maps were again generated for the region of interest and mean fluorescence intensities over the M2 region were determined for each time point. According to these quantifications, IBA-1 intensity was significantly transiently increased between 24 hours post-injection (p=0.0375) and then returns to baseline levels by the latter time point (p=0.0475) ( Figure 5C ). Presence of GFAP + astrocytes also showed temporal regulation following NP injection, but in this case demonstrated a maximal response 24 hours following the particle delivery, only to return to baseline levels by the 72 hour mark (p<0.001) and stay low at the 9 day time point (p<0.001) ( Figure 5D ).
While our data do suggest that an immune response is mounted against the particles that is greater in magnitude than that of our control saline injection, it seems that after 9 days in the brain, any inflammatory response has been normalized and the particles not only Our results support the notion that direct injection of particles could be used prior to slice preparation to directly test for greater ChR2 activation due to closer proximity and reduced light attenuation from scattering (Yona 2016) . Taken together, this report finds that the nanoparticles described here readily diffuse away from the site of injection in grey matter, while persisting in the brain up 9 days post-injection and causing a temporally regulated immune response that is no longer detectable in the injected cortex 9 days after their delivery. Particles with these properties should be highly desirable for applications of drug delivery to target brain regions or light emission for use in optogenetic studies. Nanoparticles aggregate and should be vortexed thoroughly (10 seconds) immediately before injection to maximize particle distribution. C) C. Typical range of nanoparticle spread throughout cortex. Orange polygon represents area of quantification for confocal microscopy. A) 3D render of an injection site, representative of the analysis used to approximate the spread of NPs from the M2 injection site B) Time course of the area of extent of bright NP signal adjacent to the injection site shows no change across the first 72 hours, but a sharp decline at 9 days, indicating diffusion or clearance from the injury site in that time C) Interestingly, the ratio of NP fluorescence of the ipsi-to contralateral side remained unchanged over the 9 days assayed, suggesting the persistent presence of NPs despite the diffusion from the injection site 
